The developed LC–MS/MS assay and the in vivo pharmacokinetic data would provide useful information for the further development of 177Lu-DOTA-PSMA-GUL and other structural analogs as a novel therapeutic agent for the treatment of prostate cancer. Here, FOLH1 is linked to prostate cancer.